New study expands antithrombotic options after feline ATE
Bottom line
CURRENT BRIEF VERSION: A new multicenter prospective study suggests that rivaroxaban performs about as well as clopidogrel for preventing recurrent arterial thromboembolism in cats that survived a cardiogenic thromboembolic event, adding fresh evidence to a treatment area that has long relied on clopidogrel-first practice and smaller retrospective datasets. In the SUPERCAT study, published in the Journal of the American Veterinary Medical Association in December 2024, 45 cats were randomized to receive either clopidogrel or rivaroxaban for up to two years after the initial event. Investigators reported equivalent impacts on thromboembolism recurrence and survival between the two monotherapy groups. That follows earlier UC Davis work showing dual therapy with clopidogrel plus rivaroxaban was generally tolerated in high-risk cats and associated with a relatively low recurrence rate in a retrospective series. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the new study helps move rivaroxaban from promising alternative to evidence-backed option in post-ATE management. Current consensus and review literature have favored clopidogrel, especially after the FAT CAT trial, while reserving factor Xa inhibitors or combination therapy for very high-risk patients, including cats with prior ATE, intracardiac thrombi, spontaneous echocardiographic contrast, marked left atrial enlargement, or other features tied to Virchow’s triad of stasis, endothelial injury, and hypercoagulability. SUPERCAT doesn't show superiority for rivaroxaban, but it does support it as a reasonable monotherapy choice when clopidogrel response, administration, tolerability, or adherence are concerns for the pet parent. Mechanistic work from UC Davis also suggests the clopidogrel-rivaroxaban combination may have synergistic antithrombotic effects, which helps explain why cardiologists have explored dual therapy in select cats despite limited prospective outcomes data. (pmc.ncbi.nlm.nih.gov)
What to watch: Whether this evidence changes cardiology prescribing patterns, consensus guidance, or sparks a prospective trial of dual therapy in cats most at risk for recurrence will be worth watching. It will also be worth watching how clinicians position these data alongside the separate RAPACAT/rapamycin conversation in feline cardiomyopathy, which reflects the same broader push toward more rigorous cat-specific cardiovascular evidence rather than a direct antithrombotic link. (pubmed.ncbi.nlm.nih.gov)
CURRENT FULL VERSION: A new feline cardiology study is giving clinicians a clearer answer on a familiar question: if a cat survives cardiogenic arterial thromboembolism, is rivaroxaban a viable alternative to clopidogrel for long-term prevention? According to the SUPERCAT study, published in JAVMA on December 18, 2024, the answer appears to be yes. In 45 cats randomized after recovery from cardiogenic ATE, investigators found clopidogrel and rivaroxaban had equivalent impacts on recurrent thromboembolism and overall survival. (pubmed.ncbi.nlm.nih.gov)
That matters because feline ATE remains one of the most devastating complications of cardiomyopathy, especially hypertrophic cardiomyopathy. Review literature describes recurrence as a major management challenge after the initial event, and prior guidance has leaned heavily on clopidogrel because the FAT CAT trial established it as superior to aspirin for recurrence prevention. Even so, clinicians have continued to look for better strategies because recurrent events remain common, and because real-world response to clopidogrel can vary from cat to cat. The broader pathophysiology also helps explain why prevention is difficult: Virchow’s triad still applies, with blood flow stasis, endothelial dysfunction, and hypercoagulability or platelet activation all contributing to thrombus formation, particularly in cats with marked left atrial enlargement, impaired cardiac function, intracardiac thrombi, or spontaneous echocardiographic contrast (“smoke”). (pmc.ncbi.nlm.nih.gov)
SUPERCAT was designed to address that gap more directly. The multicenter, prospective, double-masked trial enrolled 45 cats that had recovered from cardiogenic ATE and randomized them to clopidogrel at 18.75 mg/cat once daily or rivaroxaban at 2.5 mg/cat once daily for up to two years. The primary outcomes included recurrent ATE or death from any cause. While the available abstract does not provide a full breakdown of event counts in the search results, the headline finding was that the two monotherapy approaches produced equivalent recurrence and survival outcomes. (pubmed.ncbi.nlm.nih.gov)
The study builds on several earlier lines of evidence. A 2021 retrospective UC Davis case series of 32 cats prescribed clopidogrel plus rivaroxaban found dual therapy was generally tolerated, with five cats showing adverse effects potentially attributable to treatment, including bleeding signs such as epistaxis, hematemesis, hematochezia, or hematuria, and no cat requiring hospitalization because of those events. Median survival from therapy onset was 257 days overall and 502 days in cats treated after an ATE event, while the recurrence rate during dual therapy was 16.7%, and no cat developed a first ATE after starting the combination. That retrospective experience helped support what consensus groups had already been doing in the highest-risk cats: extrapolating from human medicine to use clopidogrel plus a factor Xa inhibitor such as rivaroxaban or apixaban when recurrence risk was felt to be especially high, despite the lack of definitive veterinary outcome data at the time. (abvp.com)
Mechanistic work from the same research group helped explain why combination treatment has attracted interest. In a 2023 Journal of Veterinary Internal Medicine study in healthy cats, dual antithrombotic treatment with clopidogrel and rivaroxaban reduced platelet activation and platelet-dependent thrombin generation more effectively than either drug alone, with no adverse effects seen in that small crossover study. Review authors have since described the combination as showing a potentially synergistic effect, though they also note that prospective clinical outcome data have been limited. (pubmed.ncbi.nlm.nih.gov)
For practicing veterinarians, the practical takeaway is less about declaring a winner and more about expanding the evidence base around choice of therapy. SUPERCAT suggests rivaroxaban can be considered a credible monotherapy option after cardiogenic ATE, not just an empiric substitute. That could be useful in cases where clopidogrel administration is difficult, response is uncertain, or a cardiologist is weighing a factor Xa inhibitor based on the cat's risk profile and the pet parent's ability to medicate consistently. At the same time, the earlier dual-therapy data and ex vivo platelet findings mean the conversation around combination treatment is unlikely to go away, especially for cats with intracardiac thrombi, spontaneous echocardiographic contrast, prior recurrence, or other markers of severe left-sided cardiac disease. (pubmed.ncbi.nlm.nih.gov)
There's also a broader cardiology context here. The Vet Blast framing references “building on the RAPACAT trial,” but that phrase is better understood as a nod to momentum in feline cardiology research than as a direct therapeutic bridge. RAPACAT focused on delayed-release rapamycin for subclinical feline hypertrophic cardiomyopathy, whereas SUPERCAT addresses antithrombotic prevention after ATE. In other words, these are separate studies tackling different parts of feline heart disease, but together they reflect the same shift toward more rigorous, cat-specific cardiovascular evidence. (pubmed.ncbi.nlm.nih.gov)
Why it matters: Post-ATE management is one of the hardest discussions in feline practice because prognosis, recurrence risk, quality of life, cost, and medication burden all converge quickly. This study doesn't settle the question of whether dual therapy is best for the highest-risk cats, but it does give clinicians stronger footing when discussing rivaroxaban as a single-agent option. It also reinforces that feline thromboprophylaxis is moving beyond extrapolation and anecdote toward comparative data that can support more individualized recommendations for pet parents. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step is likely more detailed uptake of the full SUPERCAT data by cardiologists, and potentially future prospective trials testing whether dual therapy improves outcomes in the highest-risk feline patients without an unacceptable bleeding tradeoff. (pubmed.ncbi.nlm.nih.gov)